Analyze Diet
Pulmonary pharmacology & therapeutics2008; 21(4); 624-629; doi: 10.1016/j.pupt.2008.02.003

Effects of neuraminidase on equine isolated bronchi.

Abstract: It has been demonstrated in mammals that the airway hyper-responsiveness, which accompanies viral infections, is the result of increased reflex bronchoconstriction due to inhibition of muscarinic prejunctional receptors, which belong to M2 subtypes. Multiple mechanisms account for virus-induced M2 receptor dysfunction. Viral neuraminidase may deglycosylate the M2 receptor, decreasing acetylcholine affinity. Equine influenza remains a common viral respiratory disease of horses worldwide, which results in loss to the equine industry, by decreasing performance, convalescence time and loss of peak performance due to chronic sequelae, such as airway hyper-responsiveness. The purpose of this study was to evaluate the effect of neuraminidase on equine isolated bronchi, assessed in equine bronchial smooth muscle rings, derived from five healthy equine male lungs. A pretreatment with vehicle did not modify contraction induced by electrical field stimulation (EFS) studies at each frequency tested. A pretreatment with pilocarpine (1-100 microM) significantly reduced, while methoctramine (1-100 microM) significantly increased contraction induced by EFS. Finally, neuraminidase (0.5 UI) significantly increased contraction induced by EFS. These results suggest that airway hyper-responsiveness that follows a viral influenza infection might be related to a dysfunction of muscarinic prejunctional receptors.
Publication Date: 2008-02-26 PubMed ID: 18394940DOI: 10.1016/j.pupt.2008.02.003Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research primarily investigates how neuraminidase, an enzyme from viruses like equine influenza, can affect horse bronchi, which may lead to a condition known as airway hyper-responsiveness. Insights from this study could potentially assist in the treatment of viral respiratory diseases in horses.

Objective and Background

  • The study aimed to understand the impact of neuraminidase on isolated bronchi from horses. Neuraminidase is an enzyme that is common in various types of viruses, including the influenza virus in horses.
  • It’s pre-established that viral infections can lead to airway hyper-responsiveness in mammals. The study implies that this likely happens due to an inhibition of specific muscarinic prejunctional receptors, classified under the M2 subtype.
  • The dysfunction of M2 receptors during viral infections can be attributed to multiple factors. One possibility is that viral neuraminidase may deglycosylate the M2 receptor to decrease its affinity for acetylcholine, which is a neurotransmitter that plays a key role in muscle contraction, including bronchial muscle.

Methodology

  • The researchers conducted the study on bronchial smooth muscle rings derived from the lungs of five healthy male horses.
  • They used electrical field stimulation (EFS) to induce contractions in these muscle rings and studied the changes upon treatment with different substances.

Findings

  • Pretreatment with a vehicle didn’t alter the contractions induced by EFS.
  • The application of pilocarpine significantly reduced the EFS-induced contraction, while methoctramine significantly increased the contraction.
  • Crucially, the application of neuraminidase resulted in a noticeable increase in the EFS-induced contraction.

Conclusion

  • The increased contraction with neuraminidase may explain the development of airway hyper-responsiveness observed in horses following influenza virus infection.
  • This suggests that the inhibition of the muscarinic prejunctional receptors, specifically the M2 subtypes, and the associated decrease in acetylcholine affinity resulting from neuraminidase activity, could contribute to the bronchoconstriction and subsequent airway hyper-responsiveness observed in horses with influenza.

Cite This Article

APA
Matera MG, Calzetta L, Sanduzzi A, Page CP, Cazzola M. (2008). Effects of neuraminidase on equine isolated bronchi. Pulm Pharmacol Ther, 21(4), 624-629. https://doi.org/10.1016/j.pupt.2008.02.003

Publication

ISSN: 1094-5539
NlmUniqueID: 9715279
Country: England
Language: English
Volume: 21
Issue: 4
Pages: 624-629

Researcher Affiliations

Matera, M G
  • Department of Experimental Medicine, Second University of Naples, Naples, Italy.
Calzetta, L
    Sanduzzi, A
      Page, C P
        Cazzola, M

          MeSH Terms

          • Animals
          • Bronchi / drug effects
          • Bronchi / pathology
          • Bronchial Hyperreactivity / etiology
          • Bronchial Hyperreactivity / veterinary
          • Bronchial Hyperreactivity / virology
          • Diamines / administration & dosage
          • Diamines / pharmacology
          • Dose-Response Relationship, Drug
          • Electric Stimulation
          • Horse Diseases / physiopathology
          • Horse Diseases / virology
          • Horses
          • Male
          • Muscarinic Agonists / administration & dosage
          • Muscarinic Agonists / pharmacology
          • Muscle Contraction / drug effects
          • Muscle, Smooth / drug effects
          • Neuraminidase / metabolism
          • Parasympatholytics / administration & dosage
          • Parasympatholytics / pharmacology
          • Pilocarpine / administration & dosage
          • Pilocarpine / pharmacology
          • Receptors, Muscarinic / metabolism
          • Viral Proteins / metabolism
          • Virus Diseases / physiopathology
          • Virus Diseases / veterinary

          Citations

          This article has been cited 2 times.
          1. Chen W, Sadatsafavi M, Tran TN, Murray RB, Wong CBN, Ali N, Ariti C, Garcia Gil E, Newell A, Alacqua M, Al-Ahmad M, Altraja A, Al-Lehebi R, Bhutani M, Bjermer L, Bjerrum AS, Bourdin A, Bulathsinhala L, von Bülow A, Busby J, Canonica GW, Carter V, Christoff GC, Cosio BG, Costello RW, FitzGerald JM, Fonseca JA, Yoo KH, Heaney LG, Heffler E, Hew M, Hilberg O, Hoyte F, Iwanaga T, Jackson DJ, Jones RC, Koh MS, Kuna P, Larenas-Linnemann D, Lehmann S, Lehtimäki LA, Lyu J, Mahboub B, Maspero J, Menzies-Gow AN, Sirena C, Papadopoulos N, Papaioannou AI, Pérez de Llano L, Perng DW, Peters M, Pfeffer PE, Porsbjerg CM, Popov TA, Rhee CK, Salvi S, Taillé C, Taube C, Torres-Duque CA, Ulrik CS, Ra SW, Wang E, Wechsler ME, Price DB. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy. J Asthma Allergy 2022;15:1491-1510.
            doi: 10.2147/JAA.S377174pubmed: 36303891google scholar: lookup
          2. Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M. Severe Asthma and Biological Therapy: When, Which, and for Whom. Pulm Ther 2020 Jun;6(1):47-66.
            doi: 10.1007/s41030-019-00109-1pubmed: 32048241google scholar: lookup